News | May 13, 2023
Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Subscribe To Our Newsletter & Stay Updated
